logo
logo
CI stock ticker logo

The Cigna Group

NYSE•CI
CEO: Mr. David Michael Cordani
Sector: Healthcare
Industry: Medical - Healthcare Plans
Listing Date: 1982-03-31
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. In addition, it offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The Cigna Group was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Contact Information
900 Cottage Grove Road, Bloomfield, CT, 06002, United States
860-226-6000
www.cigna.com
Market Cap
$71.37B
P/E (TTM)
11.9
24.3
Dividend Yield
2.3%
52W High
$350.00
52W Low
$239.51
52W Range
25%
Rank18Top 5.0%
6.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$72.47B+0.00%
4-Quarter Trend

EPS

$4.64+0.00%
4-Quarter Trend

FCF

$5.83B+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Shareholders Net Income Jumps Shareholders' net income reached $5.957B, marking a strong 73% increase compared to 2024 results.
Evernorth Revenue Growth Strong Evernorth Health Services adjusted revenues grew 16% to $234.953B, driven by pharmacy utilization increases.
HCSC Sale Completed March 2025 Completed HCSC sale in March 2025 for $4.9B cash proceeds; medical customers decreased 5% to 18,118K.
Optimization Program Costs Recorded Reported $749M pre-tax costs for enterprise-wide Strategic Optimization Program initiated in Q1 2025.

Risk Factors

Health Cost Compression Risks Profitability depends on accurately predicting and managing health care costs; insufficient premiums compress margins.
Large Client Loss Risk Loss of a single large client or unfavorable contract modification could severely impact operations and investment community reaction.
Extensive Regulatory Scrutiny Exposure Subject to fraud, abuse laws, and complex regulations; noncompliance risks fines, penalties, and operational restrictions.
Significant Indebtedness Level Total indebtedness was approximately $31.5B as of December 31, 2025, limiting flexibility for growth and reaction to economic changes.

Outlook

Supporting Rebate-Free Model Incurring investment and transition costs to support recently announced rebate-free model for pharmacy benefits over the short term.
Execute Strategic Initiatives Effectively Future performance depends on effectively implementing initiatives like growing product portfolio and improving medical cost competitiveness.
Capital Deployment Priorities Clear Prioritizing investment in technology, maintaining subsidiary financial strength ratings, repaying debt, and returning capital via repurchases.

Peer Comparison

Revenue (TTM)

CVS stock ticker logoCVS
$402.07B
+7.8%
MCK stock ticker logoMCK
$397.96B
+15.5%
COR stock ticker logoCOR
$325.78B
+7.4%

Gross Margin (Latest Quarter)

REGN stock ticker logoREGN
85.0%
+3.3pp
GSK stock ticker logoGSK
69.7%
+3.5pp
ZTS stock ticker logoZTS
68.9%
+2.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
BMY$120.31B17.139.3%52.4%
HCA$119.18B18.1-140.8%82.7%
MCK$116.13B26.7-245.3%10.2%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.4%
Moderate Growth
4Q Net Income CAGR
-2.3%
Stable Profitability
Cash Flow Stability
75%
Volatile Cash Flow

Deep Research

Next earnings:Apr 30, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data